Johnson Matthey Acquires Capacity in Scotland

December 5, 2014
Pharmaceutical Technology Editors

The Scottish plant was built by Glaxo in 1980 and will be refurbished in 2015.

Johnson Matthey announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland. The 109,000-m2 site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients using enhanced manufacturing capabilities.

Located in Annan, Dumfries and Galloway, the site was originally commissioned and constructed by Glaxo in 1980 and was most recently owned by Bakhu Pharma. A multimillion-pound refurbishment will begin in early 2015 to update and enhance the operational and quality standards of the facility. The site is expected to be fully operational by early 2016.

“This strategic site addition significantly increases our global manufacturing capabilities and capacity,” said John Fowler, division director at Johnson Matthey Fine Chemicals, in a press release. “Combining the Annan site with our leading technologies will answer our customers’ needs for efficient production of pharmaceutical intermediates and APIs at the highest quality and compliance standards in the market."

Source: Johnson Matthey

Related Content:

PharmTech News | Supplier News